1. Home
  2. DMLP vs BCAX Comparison

DMLP vs BCAX Comparison

Compare DMLP & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DMLP
  • BCAX
  • Stock Information
  • Founded
  • DMLP 2003
  • BCAX 2018
  • Country
  • DMLP United States
  • BCAX United States
  • Employees
  • DMLP N/A
  • BCAX N/A
  • Industry
  • DMLP Oil & Gas Production
  • BCAX
  • Sector
  • DMLP Energy
  • BCAX
  • Exchange
  • DMLP Nasdaq
  • BCAX NYSE
  • Market Cap
  • DMLP 1.3B
  • BCAX 1.0B
  • IPO Year
  • DMLP N/A
  • BCAX 2024
  • Fundamental
  • Price
  • DMLP $33.74
  • BCAX $18.09
  • Analyst Decision
  • DMLP
  • BCAX Strong Buy
  • Analyst Count
  • DMLP 0
  • BCAX 4
  • Target Price
  • DMLP N/A
  • BCAX $41.00
  • AVG Volume (30 Days)
  • DMLP 82.2K
  • BCAX 335.7K
  • Earning Date
  • DMLP 10-31-2024
  • BCAX 11-12-2024
  • Dividend Yield
  • DMLP 11.81%
  • BCAX N/A
  • EPS Growth
  • DMLP 4.55
  • BCAX N/A
  • EPS
  • DMLP 2.78
  • BCAX N/A
  • Revenue
  • DMLP $166,454,000.00
  • BCAX N/A
  • Revenue This Year
  • DMLP N/A
  • BCAX N/A
  • Revenue Next Year
  • DMLP N/A
  • BCAX N/A
  • P/E Ratio
  • DMLP $12.12
  • BCAX N/A
  • Revenue Growth
  • DMLP 14.26
  • BCAX N/A
  • 52 Week Low
  • DMLP $28.40
  • BCAX $17.41
  • 52 Week High
  • DMLP $35.74
  • BCAX $28.09
  • Technical
  • Relative Strength Index (RSI)
  • DMLP 63.93
  • BCAX N/A
  • Support Level
  • DMLP $32.25
  • BCAX N/A
  • Resistance Level
  • DMLP $33.72
  • BCAX N/A
  • Average True Range (ATR)
  • DMLP 0.82
  • BCAX 0.00
  • MACD
  • DMLP 0.04
  • BCAX 0.00
  • Stochastic Oscillator
  • DMLP 89.68
  • BCAX 0.00

About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests

Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.

About BCAX BICARA THERAPEUTICS INC

Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

Share on Social Networks: